Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Main|Search|PHGKB
Search PHGKB:

Last Posted: Aug 29, 2023
spot light Highlights

Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.
Gary S Ma et al. Curr Cardiol Rep 2023 8

From the abstract: "Lipoprotein(a) is an independent risk factor for cardiovascular disease. We review the ongoing shifts in consensus guidelines for the testing and management of Lp(a) and provide insight into whether current evidence suggests that awareness and testing of Lp(a) is clinically actionable."

Familial hypercholesterolaemia
S McErlean, BMJ, July 2023

Familial hypercholesterolemia is a common genetic condition affecting 1 in 310 people, resulting in premature coronary artery disease due to elevated cholesterol levels from birth If a parent has familial hypercholesterolemia, there is a 50% chance their child will inherit the condition. Treatment is based on lowering low density lipoprotein (LDL) cholesterol concentration, with a target of at least 50% reduction from baseline.

When Is a High Lipoprotein (a) Concentration Too High?-The Need for Diverse Population-Based Samples.
Sadiya S Khan et al. JAMA Cardiol 2023 5

Preclinical, epidemiologic, and genomic studies identify lipoprotein (a) (Lp[a]) as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is a low-density lipoprotein (LDL)–like particle that is bound to apolipoprotein(a) and is causally implicated in the pathogenesis of ASCVD. Despite growing evidence supporting the potential utility of Lp(a) in risk stratification for ASCVD, challenges remain in defining a cut point for what constitutes a high Lp(a) concentration. These include variation observed in Lp(a) concentrations across racial and ethnic groups, as well as differences in accuracy across various assays.

New Family Heart Foundation Study Reveals Systemic Underdiagnosis & Undertreatment of HoFH
Family Heart Foundation, May 2, 2023

A new study showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD). HoFH is a rare disease and is the most severe form of the common inherited genetic disorder called familial hypercholesterolemia (FH). HoFH leads to severely elevated low density lipoprotein cholesterol (LDL-C) from birth onward. While some with the highest LDL-C are diagnosed with HoFH in childhood, many others are missed, denying them the opportunity for timely initiation of aggressive lipid-lowering therapies (LLT) and resulting in premature cardiovascular disease.

Search Result Summary


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP